Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives

被引:27
|
作者
Al-Attraqchi, Omar H. A. [1 ]
Attimarad, Mahesh [2 ]
Venugopala, Katharigatta N. [2 ,3 ]
Nair, Anroop [2 ]
Al-Attraqchi, Noor H. A. [4 ]
机构
[1] Philadelphia Univ, Fac Pharm, POB 1, Amman 19392, Jordan
[2] King Faisal Univ, Coll Clin Pharm, Dept Pharmaceut Sci, Al Hasa 31982, Saudi Arabia
[3] Durban Univ Technol, Dept Biotechnol & Food Technol, ZA-4001 Durban, South Africa
[4] Univ Mosul, Dept Pharmacognosy, Mosul, Iraq
关键词
Adenosine A(2A) receptor; molecular modeling; myocardial perfusion imaging; Parkinson's disease; depression; cancer immunotherapy; PARKINSONS-DISEASE; MOLECULAR DOCKING; PHARMACOLOGICAL EVALUATION; PYRIMIDINE-DERIVATIVES; CANCER-IMMUNOTHERAPY; IMMUNE CHECKPOINTS; CRYSTAL-STRUCTURE; PARTIAL AGONISTS; BINDING MODE; HUMAN A(1);
D O I
10.2174/1381612825666190716113444
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine receptors (ARs) are a class of G-protein coupled receptors (GPCRs) that are activated by the endogenous substance adenosine. ARs are classified into 4 subtype receptors, namely, the A(1), A(2A), A(2B) and A(3) receptors. The wide distribution and expression of the ARs in various body tissues as well as the roles they have in controlling different functions in the body make them potential drug targets for the treatment of various pathological conditions, such as cardiac diseases, cancer, Parkinson's disease, inflammation and glaucoma. Therefore, in the past decades, there have been extensive investigations of ARs with a high number of agonists and antagonists identified that can interact with these receptors. This review shall discuss the A(2A) receptor (A(2A)AR) subtype of the ARs. The structure, properties and the recent advances in the therapeutic potential of the receptor are discussed with an overview of the recent advances in the methods of studying the receptor. Also, molecular modeling approaches utilized in the design of A(2A)AR ligands are highlighted with various recent examples.
引用
收藏
页码:2716 / 2740
页数:25
相关论文
共 50 条
  • [31] The adenosine A2A receptor is a therapeutic target in neurological, heart and oncogenic diseases
    Franco, Rafael
    Lillo, Alejandro
    Navarro, Gemma
    Reyes-Resina, Irene
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (09) : 791 - 800
  • [32] C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
    Bahrami, Afsane
    Shahidsales, Soodabeh
    Khazaei, Majid
    Ghayour-Mobarhan, Majid
    Maftouh, Mina
    Hassanian, Seyed Mahdi
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (10) : 2657 - 2673
  • [33] A2A Adenosine Receptor (A2AAR) as a Therapeutic Target in Diabetic Retinopathy
    Ibrahim, Ahmed S.
    El-shishtawy, Mamdouh M.
    Zhang, Wenbo
    Caldwell, Ruth B.
    Liou, Gregory I.
    AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (05): : 2136 - 2145
  • [34] The adenosine A2A receptor as an attractive target for Parkinson's disease treatment
    Chen, JF
    DRUG NEWS & PERSPECTIVES, 2003, 16 (09) : 597 - 604
  • [35] A2A adenosine receptor antagonists -: future drugs for Parkinson's disease?
    Müller, CE
    DRUGS OF THE FUTURE, 2000, 25 (10) : 1043 - 1052
  • [36] Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor
    Eddy, Matthew T.
    Lee, Ming-Yue
    Gao, Zhan-Guo
    White, Kate L.
    Didenko, Tatiana
    Horst, Reto
    Audet, Martin
    Stanczak, Pawel
    McClary, Kyle M.
    Han, Gye Won
    Jacobson, Kenneth A.
    Stevens, Raymond C.
    Wuthrich, Kurt
    CELL, 2018, 172 (1-2) : 68 - +
  • [37] The crystal structure of the adenosine A2A receptor-implications for drug design
    IJzerman, Adriaan Pieter
    PURINERGIC SIGNALLING, 2010, 6 : 6 - 6
  • [38] Current status and future potential of transdermal drug delivery
    Prausnitz, MR
    Mitragotri, S
    Langer, R
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (02) : 115 - 124
  • [39] Current status and future potential of transdermal drug delivery
    Mark R. Prausnitz
    Samir Mitragotri
    Robert Langer
    Nature Reviews Drug Discovery, 2004, 3 : 115 - 124
  • [40] Antibody-drug conjugates: Current status and future perspectives
    Gebleux, Remy
    Casi, Giulio
    PHARMACOLOGY & THERAPEUTICS, 2016, 167 : 48 - 59